Scientific Advisory Board
Lewis Smith is currently Professor at the University of Leicester and a consultant to Syngenta, and was formerly the Global Head of Regulatory Sciences at Syngenta. He also held positions as the Head of Health Assessment and Environmental Sciences, Syngenta and the Head of the Central Toxicology Laboratory (CTL), Zeneca. Prior to these appointments he was Professor and Director of the Medical Research Council’s Toxicology Unit at the University of Leicester.
Dr Smith currently serves and has served on numerous international committees including ILSI, HESI, Past President. He has also been on several editorial boards, including: Journal of Archives of Industrial Hygiene and Toxicology, Food & Chemical Toxicology, Human & Experimental Toxicology, Toxicology & Ecotoxicology News (TEN), Toxicology, Biochemical Pharmacology and the Journal of Toxicology and Environmental Health.
Nationally, Dr Lewis Smith served as President of the British Toxicology Society and served as Chairman of the Scientific Subcommittee, British Toxicology Society. He is also a member of the Society of Toxicology (USA), British Pharmacology Society, Biochemical Society, and a Fellow of the Royal College of Pathology and the British Toxicology Society.
Herman Autrup PhD is professor in environmental medicine, School of Public Health, University of Aarhus, Denmark. He is a member of the Danish Academy of Technical Sciences, and of the Academy of Toxicological Sciences. He has received the Frits Sobel award from the European Environmental Mutagen Society, the EUROTOX Merit Award (2013), and the SOT Education award (2014). He is president of IUTOX and chair of ILSI Health Environment Science Institute. Herman Autrup has published more than 200 papers in international peer-reviewed journals. He is currently associate editor of Toxicological Sciences and Advisory Board member of Toxicological Research.
After having previously worked as a pharmacologist in the pharmaceutical industry in the areas of asthma, skin allergy and chronic obstructive pulmonary disease, John Doe joined ICI’s Central Toxicology Laboratory (CTL) in the late 1970s. He initially worked in inhalation toxicology but then managed studies across the full spectrum of regulatory toxicology including chronic, reproductive and developmental toxicology. He worked in industrial chemical and agrochemical toxicology for many years, becoming Director of CTL in 2003 and Head of Product Safety for Syngenta in 2006. He was Chairman of ECETOC Scientific Committee from 2006 until 2010. Dr Doe retired from Syngenta in 2010 and is now an independent consultant. Dr Doe is a member of the UK Committee on Carcinogenicity. Dr Doe has a special interest in the development of new methodology for safety assessment and the application of science to the classification of chemicals.
Following periods of doctoral and post-doctoral research in toxicology, Ernie spent 13 years engaged in teaching and research in academia where his research interests centered on investigations of mechanisms of toxicity and the relationship between pharmacokinetics and toxicity. Ernie subsequently gained 21 years of operational and managerial experience in non-clinical safety evaluation within the pharmaceutical industry based in Europe and the USA. He transitioned from Head of General and Investigative Toxicology, through Senior Director of Toxicology and Scientific Director of a development site to Global Head of Scientific Affairs and Regulatory Standards within Drug Safety Assessment in Sanofi-Aventis. Since leaving industry in 2010, Ernie has held an honorary position in the Institute of Cellular Medicine at Newcastle University UK and engaged in various scientific advisory roles.
Ernie has served as Scientific Meetings Secretary of the British Toxicology Society (BTS) and is currently Vice President of the BTS. Ernie has also contributed to EUROTOX as President and Chair of several committees. He is a Fellow of the BTS, a Fellow of the Academy of Toxicological Sciences and an Honorary Member of EUROTOX. He has served on several expert committees, including the Safety, Efficacy and Adverse Reactions Committee of the UK Committee on Safety of Medicines. He has had leadership roles in a number of scientific consortia on both sides of the Atlantic serving as Chair of the Washington DC based ILSI Health and Environmental Sciences Institute (HESI) Renal Biomarkers Committee (now Scientific Advisor to this committee) and Vice Chair of the ILSI HESI Emerging Issues Committee and as a member of the Advisory Committee of the Predictive Safety Testing Consortium of the Critical Path Institute. Currently, he is Vice Chair of the Board of Trustees, Executive Committee and Program Strategy and Stewardship Committee of ILSI HESI and Chair of the Scientific Advisory Board of the UK public private partnership, Stem Cells for Safer Medicines. He has published more than 90 journal articles, reviews and book chapters and is a member of the editorial boards of Toxicology Letters and Human & Experimental Toxicology.
Dr Bus has over 35 years of toxicology experience focused on research and evidence-based literature analyses informing potential health risks associated with chemical and pesticide exposures.
Dr Bus is currently Senior Managing Scientist Toxicology & Mechanistic Biology at Exponent. Dr Bus’ experience includes over 23 years as a consulting toxicologist in the Toxicology and Environmental Research and Consulting unit of The Dow Chemical Company. He previously held positions at the Upjohn Company, the Chemical Industry Institute of Toxicology, and as Assistant Professor of Toxicology at the University of Cincinnati. Across all of these positions he focused on providing consulting and research expertise in support of health risk evaluations of environmental and industrial chemicals and pesticide and pharmaceutical products.
Dr Bus has served as President of the Society of Toxicology, the American Board of Toxicology, and the Academy of Toxicological Sciences, and as a Director of the International Union of Toxicology. He has served on various toxicology-related advisory Boards and Panels including: ILSI-HESI and ILSI Research Foundation; the American Chemical Council Long-Range Research Strategic Science Team; both EPA ORD Board of Scientific Counselors and Chartered Science Advisory Board; the National Academy of Sciences Board on Environmental Studies and Toxicology; the National Institutes of Environmental Health Sciences/National Toxicology Program Board of Scientific Counselors (Technical Reviews Subcommittee); the FDA National Center for Toxicology Research Science Advisory Board; and Board of Directors of the Hamner Institutes. In addition, Dr Bus served on the Chemical Substances (TLV) Committee of the American Conference of Governmental and Industrial Hygienists, the Program Committee of the Toxicology Forum, and advisory boards of the University of Michigan and Purdue University. He is an Adjunct Professor in the Department of Pharmacology and Toxicology at Michigan State University.
His research interests include toxicokinetic mechanisms mediating dose-dependent expression of chemical toxicity. He has over 120 research and review publications and has received both the Achievement Award and Founder’s Award from the Society of Toxicology in recognition of his research and leadership in toxicology.
Dr Mark Graham has 28 years experience of Pharmaceutical Toxicology, including 14 years at AstraZeneca, where he was Senior Principal Scientist and Global Discipline Leader for Discovery Toxicology. Dr Graham has a track record of identifying mechanistic explanations in order to facilitate translational assessment of risk for humans. He has successfully applied this approach at all stages of drug discovery and development – from target identification to product registration.
As well as his industrial experience, Dr Graham has remained active in toxicological research by collaborating with several Universities, resulting in many peer reviewed scientific publications. Dr Graham is a Fellow of the British Toxicology Society and a Member of the Committee On Toxicity (COT) which provides expert advice on chemical toxicity to the UK Government. Dr Graham is also a member of the editorial board of the journal Xenobiotica.